HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

COVID-19 Induced Acute Respiratory Distress Syndrome-A Multicenter Observational Study.

Abstract
Background: Proportions of patients dying from the coronavirus disease-19 (COVID-19) vary between different countries. We report the characteristics; clinical course and outcome of patients requiring intensive care due to COVID-19 induced acute respiratory distress syndrome (ARDS). Methods: This is a retrospective, observational multicentre study in five German secondary or tertiary care hospitals. All patients consecutively admitted to the intensive care unit (ICU) in any of the participating hospitals between March 12 and May 4, 2020 with a COVID-19 induced ARDS were included. Results: A total of 106 ICU patients were treated for COVID-19 induced ARDS, whereas severe ARDS was present in the majority of cases. Survival of ICU treatment was 65.0%. Median duration of ICU treatment was 11 days; median duration of mechanical ventilation was 9 days. The majority of ICU treated patients (75.5%) did not receive any antiviral or anti-inflammatory therapies. Venovenous (vv) ECMO was utilized in 16.3%. ICU triage with population-level decision making was not necessary at any time. Univariate analysis associated older age, diabetes mellitus or a higher SOFA score on admission with non-survival during ICU stay. Conclusions: A high level of care adhering to standard ARDS treatments lead to a good outcome in critically ill COVID-19 patients.
AuthorsJohannes Herrmann, Elisabeth Hannah Adam, Quirin Notz, Philipp Helmer, Michael Sonntagbauer, Peter Ungemach-Papenberg, Andreas Sanns, York Zausig, Thorsten Steinfeldt, Iuliu Torje, Benedikt Schmid, Tobias Schlesinger, Caroline Rolfes, Christian Reyher, Markus Kredel, Jan Stumpner, Alexander Brack, Thomas Wurmb, Daniel Gill-Schuster, Peter Kranke, Dirk Weismann, Hartwig Klinker, Peter Heuschmann, Viktoria Rücker, Stefan Frantz, Georg Ertl, Ralf Michael Muellenbach, Haitham Mutlak, Patrick Meybohm, Kai Zacharowski, Christopher Lotz
JournalFrontiers in medicine (Front Med (Lausanne)) Vol. 7 Pg. 599533 ( 2020) ISSN: 2296-858X [Print] Switzerland
PMID33392222 (Publication Type: Journal Article)
CopyrightCopyright © 2020 Herrmann, Adam, Notz, Helmer, Sonntagbauer, Ungemach-Papenberg, Sanns, Zausig, Steinfeldt, Torje, Schmid, Schlesinger, Rolfes, Reyher, Kredel, Stumpner, Brack, Wurmb, Gill-Schuster, Kranke, Weismann, Klinker, Heuschmann, Rücker, Frantz, Ertl, Muellenbach, Mutlak, Meybohm, Zacharowski and Lotz.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: